Alkermes (ALKS) Receivables (2011 - 2026)
Alkermes (ALKS) posted quarterly Receivables of $456.5 million for Q2 2026, up 28.11% year-over-year from $356.3 million in Q2 2025, and up 11.98% quarter-over-quarter from $407.6 million in Q1 2026.
Alkermes (ALKS) Receivables (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Receivables for 16 consecutive years, with $456.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Receivables rose 28.11% year-over-year to $456.5 million; the TTM figure through Jun 2026 stood at $456.5 million (up 28.11% YoY), while the FY2025 annual figure was $399.8 million, down 11.94% from the prior year.
- Receivables advanced to $456.5 million in Q2 2026 per ALKS's latest filing, from $407.6 million in the prior quarter.
- Across five years, Receivables topped out at $456.5 million in Q2 2026 and bottomed at $1.4 million in Q4 2023.
- Historically, Receivables has averaged $309.9 million across 5 years, with a median of $337.5 million in 2023.
- Annual changes were most pronounced in 2023 — Receivables plunged 98.26% — and 2024, when it surged 27486.26%.
- Alkermes' Receivables stood at $80.9 million in 2022, then slumped by 98.26% to $1.4 million in 2023, then soared by 27486.26% to $389.5 million in 2024, then rose by 2.65% to $399.8 million in 2025, then increased by 14.17% to $456.5 million in 2026.
- Business Quant data shows ALKS's Receivables at $456.5 million in Q2 2026, $407.6 million in Q1 2026, and $399.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 1.08 Bn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 456.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 456.48 Mn |
| Mar 31, 2026 | 407.63 Mn |
| Dec 31, 2025 | 399.83 Mn |
| Sep 30, 2025 | 355.11 Mn |
| Jun 30, 2025 | 356.33 Mn |
| Mar 31, 2025 | 321.75 Mn |
| Dec 31, 2024 | 389.52 Mn |
| Sep 30, 2024 | 370.18 Mn |
| Jun 30, 2024 | 369.91 Mn |
| Mar 31, 2024 | 317.08 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 340.46 Mn |
| Jun 30, 2023 | 334.48 Mn |
| Mar 31, 2023 | 277.61 Mn |
| Dec 31, 2022 | 80.93 Mn |
| Sep 30, 2022 | 267.28 Mn |
| Jun 30, 2022 | 262.33 Mn |
| Mar 31, 2022 | 270.15 Mn |
| Dec 31, 2021 | 140.96 Mn |
| Sep 30, 2021 | 292.67 Mn |